Sandoz To Delay Launch Of Its Neupogen Biosimilar
This article was originally published in The Pink Sheet Daily
Executive Summary
Sandoz will not launch its filgrastim until the earlier of April 10 or a favorable court ruling in litigation over its compliance with the biosimilar statute; if Sandoz wins dispute it will give Amgen five days’ notice of a launch.